<DOC>
	<DOCNO>NCT00299325</DOCNO>
	<brief_summary>Primary objective : To assess effect rimonabant visceral fat area period 12 month prescribe mild hypocaloric diet abdominally obese patient metabolic syndrome Secondary objective : - To assess effect rimonabant period 12 month : - Liver fat content use CT scan ( Computed Tomography scan ) - Anthropometric measure ( weight , waist circumference , body composition use Dual Energy X-ray Absorptiometry ( DEXA ) ) - Lipid , lipoprotein profile - Glycemia , insulinemia HbA1c - Adipokines , inflammatory hemostatic marker - To evaluate percentage patient metabolic syndrome 12 month - To evaluate safety tolerability rimonabant patient In four select US site effect rimonabant 12 month also assess : - Basal lipolysis insulin suppress lipolysis ( euglycemic hyperinsulinemic clamp ) . - Resting metabolic rate substrate oxidation rest use indirect calorimetry . - Adipose tissue histology expression gene involve glucose lipid metabolism ( superficial adipose tissue biopsy ) .</brief_summary>
	<brief_title>VIsceral Fat Reduction Assessed CT-scan On RImonabAnt</brief_title>
	<detailed_description>The total duration per patient approximately 15 month include 12-month double-blind treatment period .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Inclusion criterion : Waist circumference &gt; 102 cm men &gt; 88 cm woman Two component metabolic syndrome ( NCEP/ATPIII definition ) among follow : Triglyceridemia ≥ 150 mg/dl ( 1.69 mmol/L ) HDL cholesterol &lt; 50 mg/dL ( 1.29 mmol/L ) woman &lt; 40 mg/dL ( 1.04 mmol/L ) men Blood pressure ≥ 130/85 mmHg ( systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg ) Treatment antihypertensive agent ( ) condition Fasting blood glucose &gt; 110 mg/dl ( 6.1 mmol/L ) Exclusion criterion : Positive pregnancy test , pregnant breastfeed woman , woman plan become pregnant breastfeed Absence medically approve contraceptive method female childbearing potential History lowcalorie diet ( ≤ 800 kcal/day ) within 3 month prior screen visit History surgical procedure weight loss ( eg , stomach stapling , bypass ) . Presence clinically significant endocrine disease accord investigator . Weight change &gt; 5 kg within 3 month prior screen visit Obese patient ( BMI &gt; 40 kg/m² ) Established type 1 2 diabetes ( treat untreated ) : least 2 measure fast blood glucose ≥ 126 mg/dl Severe renal dysfunction ( creatinine clearance &lt; 30 ml/min ) nephrotic syndrome Chronic hepatitis clinically significant hepatic disease Positive test hepatitis B C Marijuana hashish user Significant haematology abnormality ( haemoglobin &lt; 100 g/L and/or neutrophil &lt; 1.5 G/L and/or platelet &lt; 100 G/L ) . Presence history cancer within past 5 year exception adequately treat basal cell skin cancer situ uterine cervical cancer Presence history severe depression define depression necessitate patient hospitalise , patient 2 recurrent episode depression history suicide attempt Presence history bulimia anorexia nervosa ( DSMIV ( Diagnostic Statistical Manual Mental Disorders ) criterion ) binge eat disorder Presence condition ( eg geographical , social… ) current anticipate Investigator feel would restrict limit subject 's participation duration studyRelated previous concomitant drug could interfere evaluation study drug effect Administration investigational treatment ( drug device ) within 30 day prior screen Previous participation rimonabant study Administration follow within 3 month prior screen visit : anti obesity drug ( eg , sibutramine , orlistat ) drug weight reduction ( phentermine , amphetamine ) herbal preparation weight reduction thyroid preparation thyroxin treatment ( except patient replacement therapy stable dose ) Patient treat within last 3 month nicotinic acid , fibrates , bile acid sequestrants ezetimibe ( patient treat statin include dose receive stable since least 3 month modify whole study period ) . Patient treat antidiabetic drug ( ) . Prolonged use ( one week ) within last 3 month systemic corticosteroid , neuroleptic , antidepressant ( include bupropion ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>